AM-Pharma announces appointment of Chief Business Officer

September 17 2007 | Category: Appointment

Bunnik, The Netherlands, 17 September 2007. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins to combat disease, today announced the appointment of Erik van den Berg as Chief Business Officer.

Erik van den Berg MSc MBA, joins from Organon, where he was leading the global biotech business development efforts. Prior to joining Organon, he worked in business and corporate development with biotech company IsoTis and as management consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships.

Bart Wuurman, CEO commented: “We expect to out-license our products to world-wide development and marketing partners once we have generated further clinical proof of safety and efficacy of our products in Phase II trials. Therefore we are very pleased that Erik, who has outstanding experience with product licensing and corporate development, has joined our team to fill the key position of Chief Business Officer.”

Erik van den Berg added: “I am excited about joining the AM-Pharma team. The two acute hospital care products AM-Pharma is developing, which address large markets, are becoming increasingly attractive for partnering as more Phase II data becomes available.”

Download this press release (61 kB, pdf)

Latest News

October 24 2018
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
Read more.

March 9 2018
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Read more.

News Categories


Upcoming Events

For a full list of the events we will be attending this year
Click here.